secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0000950170-22-016467
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Biosciences reports Q2 2022 net loss of $11.9M; cash $99.1M; updates on CAH trials and leadership
--------------------------------------------------------------------------------

- Net loss of $11.9M for Q2 2022 (vs $11.8M Q2 2021); R&D spend $9.1M, flat YoY.
- Cash, equivalents and investments $99.1M as of June 30, 2022.
- CAHmelia-203 surpassed 25% enrollment; CAHmelia-204 approaching 25% enrollment.
- Appointed P.J. Ramtin as SVP of Business Operations; two new tildacerfont method-of-use patents issued, exclusivity through 2038.
- Abstract on Phase 2a CAH data accepted for oral presentation at ICE 2022 (Aug 27).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000095017022016467/0000950170-22-016467-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000095017022016467/sprb-20220810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016467

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer